Plasma therapy of primary rat mammary carcinoma: antitumor activity of tumor-bearer plasma adsorbed against inactivated CNBr sepharose or protein A-sepharose.
We evaluated the ability of plasma adsorbed against Sepharose, inactivated CNBr Sepharose, or protein A-Sepharose to inhibit the growth of primary mammary carcinomas in Buffalo/N rats. Mammary adenocarcinomas were induced by a single intravenous injection of N-nitroso N-methylurea. When palpable mammary tumors were detected, rats were treated by infusion of plasma obtained from normal or tumor-bearing rats. Animals were killed 50 days after entry into the experiment; the index mammary tumor and any subsequently arising tumors were weighed and examined histologically. Unadsorbed plasma obtained from normal or tumor-bearing rats had no detectable antitumor effect. Normal plasma adsorbed against Sepharose or Sepharose derivatives had no significant antitumor effect. Weight (median) of index mammary tumors in groups of rats treated with normal plasma adsorbed against Sepharose alone, inactivated CNBr Sepharose alone, or protein A--Sepharose alone was not significantly different from weight of tumors of untreated, control animals. Tumor-bearer plasma adsorbed against either inactivated CNBr Sepharose or protein A-Sepharose had significant antitumor effect. Weight of index mammary tumors in groups of rats treated with tumor-bearer plasma adsorbed to inactivated CNBr Sepharose alone or against protein A-Sepharose alone was significantly less than weight of tumors in control rats. Tumor-bearer plasma adsorbed against Sepharose alone inhibited tumor growth in one experiment but not in a second experiment. Tests for endotoxin in CNBr Sepharose indicated the presence of approximately 1 ng endotoxin/g Sepharose. Administration of nanogram quantities of Salmonella enteritidis endotoxin in saline did not inhibit growth of primary mammary tumors. These experiments describe a rodent model that may be useful in the analysis of the basis of the inhibition of tumor growth that occurs following administration of adsorbed plasma.
D000818:Animals; D003488:Cyanogen Bromide / Q000494:pharmacology; D005260:Female; D007163:Immunosorbent Techniques; D008325:Mammary Neoplasms, Experimental / Q000097:blood / Q000628:therapy*; D051381:Rats; D012685:Sepharose / Q000494:pharmacology; D013205:Staphylococcal Protein A / Q000627:therapeutic use*
D013205:Staphylococcal Protein A; D012685:Sepharose; D003488:Cyanogen Bromide